Exero Medical's flagship product, the xBar system, uses sensors placed at the surgical site to collect tissue-healing data that can help clinicians detect major, life-threatening post-operative complications earlier. The xBar has received FDA Breakthrough Device Designation and is currently limited to investigational use in the United States. The company plans to complete an FDA pivotal trial and launch the xBar system in the U.S.; it has established a new U.S. headquarters at Scitech Scity at the Liberty Science Center in Jersey City, NJ to support clinical and commercial activities. Exero was founded in 2018 by MEDX Xelerator and is backed by public- and private-sector supporters named in the company's materials. Financially, Exero has secured financing to advance its regulatory program and U.S. expansion. The company emphasizes improving patient outcomes and reducing costs by adding new postoperative health data into clinical workflows.

Total raised

$13M

Funding rounds

2

Latest round

Grant

Latest activity

Feb 2025